Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). - Wikidata - awgldk - TriplyDB

Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

http://www.wikidata.org/entity/Q36618624

about

Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.HER2 and breast cancer stem cells: more than meets the eye.Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.CD147 monoclonal antibody mediated by chitosan nanoparticles loaded with α-hederin enhances antineoplastic activity and cellular uptake in liver cancer cells.Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.The voltage gated Ca(2+)-channel Cav3.2 and therapeutic responses in breast cancer Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties.Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment.When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase.MiR-34a modulates ErbB2 in breast cancer.Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells.Genome network medicine: innovation to overcome huge challenges in cancer therapy.CD49f Can Act as a Biomarker for Local or Distant Recurrence in Breast Cancer.Cancer heterogeneity and signaling network-based drug target.Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma.Establishment and characterization of three stable Basal/HER2-positive breast cancer cell lines derived from Chinese breast carcinoma with identical missense mutations in the DNA-binding domain of TP53

P2860

Q33566597-94D801AF-17E7-43CF-9890-B85555DE3A26 Q34103963-DEC1E0D0-34C7-4513-96D3-3F36054C4FE6 Q35320325-2BE02F33-5DEC-48D8-987A-5A374CEE7692 Q35740160-C1526F4E-8FF6-4DF7-817B-718B21E3ECFF Q36350566-298F3A5E-FD94-4BE5-8883-8B58B870FD0D Q36544839-98A185DA-0EC5-499C-84A0-35424897AF20 Q36749041-F73C3612-8D52-4896-86E0-048FA0B042A0 Q36781090-CD6562E2-080E-44D0-BA75-A57408B61F50 Q36898399-3A246B52-66B0-456F-A088-52F20D380C2F Q36963419-3576EB50-5E60-4113-8DFF-8EC252106F89 Q37543832-3098A13F-3E6F-47FE-9EF7-BEC2C064C8D0 Q38673589-125C0C7E-DA5C-4404-823E-7ADCC2D0133F Q38733014-646176C5-73B5-473F-B202-CA0BC21BB326 Q38913316-28AD26E2-F01D-45D1-BE39-411376577FE3 Q39299026-C78D7724-9374-4881-ABA2-5E03B3D79BF6 Q40953798-B7F318AC-D671-4BB5-B427-99D6712EAE17 Q45299621-7E8EB867-E10D-4F21-8BEC-18797CC1AC6E Q47114555-7B686A46-8700-4D72-BC81-8884B56B02DD Q58770540-9111FC2C-367A-477E-BB6A-B773A8421849

P2860

Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

http://www.wikidata.org/entity/Q36618624

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Basal/HER2 breast carcinomas: ...... ce to trastuzumab (Herceptin).

@ast

Basal/HER2 breast carcinomas: ...... ce to trastuzumab (Herceptin).

@en

type

label

Basal/HER2 breast carcinomas: ...... ce to trastuzumab (Herceptin).

@ast

Basal/HER2 breast carcinomas: ...... ce to trastuzumab (Herceptin).

@en

prefLabel

Basal/HER2 breast carcinomas: ...... ce to trastuzumab (Herceptin).

@ast

Basal/HER2 breast carcinomas: ...... ce to trastuzumab (Herceptin).

@en

P1433

Q36618624-0320F4DF-1883-4559-A922-72B72039875F

P1476

Q36618624-4E273028-8C0C-4C0F-9706-5898A0997035

P2093

Q36618624-334F299B-52B0-4F18-BD7C-2A4C97025961

Q36618624-534E25C4-8611-4282-B997-0A64307EDC90

Q36618624-6678DAC7-BDD8-405D-890B-754147BFB6B1

Q36618624-7E5AA911-444D-4048-B373-B0691E574BA6

Q36618624-7EA820C7-D154-42FD-BAE5-3C3565B755C8

Q36618624-94D1F00F-7A0E-44EC-B68A-13307F60F22E

Q36618624-B70650C2-A4BD-4652-867D-7244F6C24286

Q36618624-CB8DB005-51F2-4443-811A-A19654D0C0AF

P2860

Q36618624-00350CE5-6D95-47B2-99DA-8FA46D4E6058

Q36618624-00BFF8E8-F49B-4F1C-8F41-E91A95EAFAC8

Q36618624-0143BDA5-41A1-4806-A263-1DC67B7F6EFE

Q36618624-022A0086-AEF0-47E1-AF14-79D7978CFB7A

Q36618624-0279D623-B00F-4B20-9289-DB8B95EEF20F

Q36618624-0376DBDB-3845-4C9F-97A5-865FC42865D1

Q36618624-041E53DD-ED24-4E5F-8975-96E49C4D9F22

Q36618624-06445B3F-510B-42D5-AF09-CE27B5CC4773

Q36618624-081EC116-C66D-46CD-870C-95F92B0F7476

Q36618624-0C49E861-8F0A-4389-92D8-8CB6F0252E81

P304

Q36618624-DF4556BD-E669-4501-94C9-573BBBBDBE79

P31

Q36618624-DA9A3D08-87B7-433C-985C-5271125E2452

P356

Q36618624-F68608D7-4538-4F01-88D9-EB6C1712A0F5

P433

Q36618624-E5CB9097-AEED-42BA-9B3B-DA199BD8847D

P478

Q36618624-699C8A3B-E845-4DB5-9D75-DB1EE89C39A5

P50

Q36618624-9F823CBC-7251-48E8-AC8E-DA8BF3D00103

Q36618624-D116CF44-07D3-4634-82AE-267D4032B43F

P577

Q36618624-A7CF0731-6928-436F-A751-932246921EA8

P698

Q36618624-8EDE250F-D4E7-4F4A-A1FF-E2E2F79A6111

P932

Q36618624-285ABF11-F424-4C63-AB5B-3E10E1D0B408

P356

P1433

P1476

Basal/HER2 breast carcinomas: ...... nce to trastuzumab (Herceptin)

@en

P2093

Alejandro Vazquez-Martin

http://www.w3.org/2001/XMLSchema#string

Begoña Martin-Castillo

http://www.w3.org/2001/XMLSchema#string

Bruna Corominas-Faja

http://www.w3.org/2001/XMLSchema#string

Cristina Oliveras-Ferraros

http://www.w3.org/2001/XMLSchema#string

Eugeni López-Bonet

http://www.w3.org/2001/XMLSchema#string

José Manuel Moreno

http://www.w3.org/2001/XMLSchema#string

Silvia Cufí

http://www.w3.org/2001/XMLSchema#string

Ángel G Martín

http://www.w3.org/2001/XMLSchema#string

P2860

The CD44+/CD24- phenotype is enriched in basal-like breast tumors

Negative regulation of the expressions of cytokeratins 8 and 19 by SLUG repressor protein in human breast cells

Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress

Breast cancer in the personal genomics era

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

Prospective identification of tumorigenic breast cancer cells

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

Many ribosomal protein genes are cancer genes in zebrafish

P304

225-245

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CC.23274

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Ander Urruticoechea

Javier A Menendez

P577

2012-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23255137

http://www.w3.org/2001/XMLSchema#string

P932

3575452

http://www.w3.org/2001/XMLSchema#string